The European regulator recommends granting pediatric use marketing authorization for Bopediat to treat children with oedema ...

HF results in pulmonary and peripheral edema due to a decrease in cardiac output and retention of free water by the renal tubules. This fluid retention causes dyspnea, orthopnea and fatigue leading to ...

Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure. Last year, the drug developer noted that FDA feedback from a 2023 Type D ...

Credit: SQ Innovation. The Lasix ONYU is a drug-device combination therapy that allows for subcutaneous infusion of furosemide, a loop diuretic. The pre-programmed device delivers 30mg of furosemide ...

Subcutaneous (SC) furosemide, a novel way to deliver diuretic therapy, may improve symptoms and functional capacity in patients with heart failure (HF) and worsening congestion, according to results ...

DEAR DR. ROACH: Your recent column regarding edema from venous insufficiency caught my interest since I was diagnosed with venous insufficiency over 25 years ago. Your recommendation was to raise your ...

Furosemide, a water tablet prescribed for managing conditions like heart failure and elevated blood pressure, is an important medication for countless Brits. The drug, which was issued roughly 11 ...

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for Injection in the ...

Furoscix is expected to be available for CKD patients in April 2025. The Food and Drug Administration (FDA) has expanded the approval of Furoscix ® (furosemide injection) to include the treatment of ...

The pre-programmed device delivers 30mg of furosemide over the first hour followed by 12.5mg per hour for the subsequent 4 hours. The Food and Drug Administration (FDA) has approved Lasix ® ONYU ...